A Study of Cognitive Health in Survivors of Prostate Cancer

Memorial Sloan Kettering Cancer Center (Other)
Overall Status
CT.gov ID

Study Details

Study Description

Brief Summary

The purpose of this study is to collect information that may help the researchers understand the relationship between prostate cancer survivors' experiences of cancer-related cognitive dysfunction (CRCD) and their other conditions (co-morbid factors), including anxiety, depression, and insomnia. The researchers will also find out how additional things may contribute to CRCD, including social factors, the characteristics of participants' prostate cancer, and the type of cancer treatment or other medications they received.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: PROMIS-SF v2.0 -Cognitive Function 8a

Study Design

Study Type:
Anticipated Enrollment :
200 participants
Observational Model:
Time Perspective:
Official Title:
Prostate Cancer Survivorship and Cognitive Health (PRO-HEALTH)
Actual Study Start Date :
Sep 8, 2022
Anticipated Primary Completion Date :
Sep 8, 2024
Anticipated Study Completion Date :
Sep 8, 2024

Arms and Interventions

Arm Intervention/Treatment
Survivors of Prostate Cancer

Behavioral: PROMIS-SF v2.0 -Cognitive Function 8a
Patient-Reported Outcomes (PROs)

Outcome Measures

Primary Outcome Measures

  1. number of participants with co-morbid symptoms [1 year]

    All participants will be evaluable as long as they have completed the PROMIS-SF v2.0 - Cognitive Function 8a.

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Inclusion Criteria:
  • English-speaking

  • Age 18 years or older

  • History of histologically documented PC of any stage

  • Undetectable PSA levels

Exclusion Criteria:
  • <1 month since completion of surgery, radiation, chemotherapy, or ADT

  • Greater than 10 years since PC diagnosis

  • Diagnosis of Alzheimer's disease, vascular dementia, Parkinson disease, or other organic brain disorder

  • Score >10 indicative of dementia on Blessed Orientation Memory Concentration

Contacts and Locations


Site City State Country Postal Code
1 Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey United States 07920
2 Memorial Sloan Kettering Monmouth Middletown New Jersey United States 07748
3 Memorial Sloan Kettering Bergen Montvale New Jersey United States 07645
4 Memorial Sloan Kettering Cancer Center Suffolk - Commack Commack New York United States 11725
5 Memorial Sloan Kettering Westchester Harrison New York United States 10604
6 Memorial Sloan Kettering Cancer Center New York New York United States 10065
7 Memorial Sloan Kettering Nassau Uniondale New York United States 11553

Sponsors and Collaborators

  • Memorial Sloan Kettering Cancer Center


  • Principal Investigator: Kevin Liou, Memorial Sloan Kettering Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:


None provided.
Responsible Party:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
Other Study ID Numbers:
  • 22-223
First Posted:
Sep 15, 2022
Last Update Posted:
Sep 15, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Memorial Sloan Kettering Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 15, 2022